Our Technology





Oxyless has developed a novel, USA and EU patented, CE mark bloodline that has universal application in the routine dialysis setting.

FDA 510(k) clearance was received in February 2016.

The Oxyless arterial expansion chamber reduces the contact between blood and air by 99.1%. This leads to a reduction in the degradation of blood during dialysis treatments, thus improving red cell survival.

Clinical use of the Oxyless bloodline in Europe has shown that it leads to a reduction in the need for Erythropoietin Simulating Agents (ESAs) that are routinely used in hemodialysis procedures worldwide.

This could have significant financial benefits for healthcare providers.








Oxyless has developed a novel, USA and EU patented, CE Mark bloodline that has universal application in the routine dialysis setting.





The Oxyless bloodline, reduces the contact between blood and air, circa 90%. This leads to a reduction in the degradation of blood during dialysis treatments, thus improving red cell survival





Clinical use of the Oxyless bloodline has shown that it leads to a reduction in the need for Erythropoietin Simulating Agents (ESAs) that are routinely used in haemodialysis procedures worldwide.





This will have significant financial benefits for healthcare providers both in terms of immediate cost reduction and competitive advantage.